phisms [31I (T/A)] of Aurora-A were genotyped. Odds ratios and 95% confidence intervals were obtained using unconditional logistic regression analysis. RESULTS: A total of 30 with oral cancer and 30 controls were genotyped for SNP. The data indicated that the homozygous variant genotype (AA) was associated with a significantly increased oral cancer risk. However, the individuals with heterozygous genotype (TA) were not associated with oral cancer risk. CONCLUSION: This is the first epidemiological study to report significant associations between Aurora-A [F31I] SNP and oral cancer risk.
PPAR␥ Mediated Transdifferentiation of Head and Neck Cancer
Nathan Johnson (presenter); Frank Ondrey, MD, PhD; Beverly Wuertz OBJECTIVE: 1) To explore whether PPAR␥ activators (PGJ2, pioglitazone, and bexarotene) induce adipocyte transdifferentiation in pre-neoplastic head and neck cell lines (HOK-16B, MSK-Leuk) and a cancer cell line . 2) To evaluate differentiation markers following treatment with PPAR gamma activators. METHOD: Cells were treated with PPAR␥ activators and the adipocyte differentiation marker FABP4 was evaluated by plate luminometry, semi-quantitative RT-PCR, and agarose gel electrophoresis. Cellular proliferation was analyzed by MTT cell proliferation assays and cell counting. Oil Red O cell staining was used to quantitate lipid accumulation in differentiated cells. Student's t-test was performed for all experiments. RESULTS: Significant dose-dependent increases in the expression of FABP4 (a marker of adipocyte differentiation) occurred in response PPAR␥ activation with pioglitazone in combination with bexarotene. In HOK cells, FABP4 promoter activity increased 4 fold, in MSK cells promoter activity increased 1.8 fold. Treatment with PPAR activators decreased cell proliferation in a dose-dependent manner as judged by MTT and cell counting assays. Lipid accumulation also increased after PPAR␥ activator treatment. CONCLUSION: PPAR␥ activators can induce adipocyte differentiation of pre-neoplastic cell lines at clinically achievable doses. Decreased cancer cell proliferation secondary to PPAR␥ activation has been observed in upper aerodigestive and other cancers. PPAR␥ activation and adipocyte transdifferentiation induction may be another anti-cancer mechanism for PPAR␥ activators potentially providing additional unique clinical trial biomarkers.
Predicting Thyroxine Requirements After Total Thyroidectomy
Dipan Mistry, MB, ChB, FRCS (presenter); Stephen Atkin, MD, PhD; Helen Atkinson, MBBS; James England, MB, ChB, FRCS OBJECTIVE: To determine the best estimate for the initial replacement dose of levothyroxine immediately following total thyroidectomy. METHOD: Prospective study undertaken at Hull Royal Infirmary, a secondary care provider in the UK. One hundred consecutive adult patients (between August 2001 and January 2009) underwent total thyroidectomy for non-malignant disease. All patients were initiated on 100 micrograms levothyroxine and titrated to within the reference range for TSH and free T4. Correlations to height, weight, age, lean body mass (LBM), body surface area (BSA) and body mass index (BMI) were calculated. Comparison between three methods of levothyroxine dose prediction was carried out, aiming for a levothyroxine dose correct to within 25 micrograms of actual dose required. Correlation, multiple step-wise regression and analysis of variance (ANOVA) was carried out using SPSS 16.0. RESULTS: Levothyroxine replacement dose correlated with age of patient (r ϭ -0.346, pϽ0.01), LBM (0.312, pϽ0.01), BSA (0.319, pϽ0.01), bodyweight (0.296, pϽ0.01) and BMI (0.172, pϽ0.05). A regression equation was calculated (predicted levothyroxine dose ϭ [0.943 x body weight] ϩ [-1.165
x age] ϩ 125.8). For pragmatic reasons, this was simplified (levothyroxine dose ϭ bodyweight -age ϩ 125). Initiating patients empirically on 100 micrograms postoperatively showed that 40% of patients achieved target within 25 micrograms of their required dose; this increased to 59% when using a weight-only dose calculation (1.6micrograms/kg), and to 72% using the simplified regression equation. CONCLUSION: The simple calculated regression equation gives a more accurate initial levothyroxine dose following total thyroidectomy, reducing the need to attend for dose titration.
Predictors of Malignancy in Head and Neck Paragangliomas
David Chapman, MD (presenter); Catherine Rees, MD; Dylan Lippert; Gregory Russell, MS; J Browne, MD OBJECTIVE: To identify salient factors that may predict malignancy in head and neck paragangliomas. METHOD: A retrospective review of head and neck paragangliomas diagnosed and/or treated at our institution from 1976 to current was completed. RESULTS: Of the 84 subjects, there were 7 malignant paragangliomas (8%). Age was found to be significantly different between the benign and malignant subgroups, with an average age of 54ϩ/-16 and 40ϩ/-12 years, respectively (pϭ0.02). Pain was a presenting complaint in 5 patients with benign disease (6%), while 5 of the 7 (71%) patients with malignant disease presented with pain (pϽ0.0001). The odds ratio for a patient with pain having a malignant tumor present was 36 (95% CI: 5.5, 234). Subjective complaint of enlarging neck mass was noted in all cases of malignant disease, but only in P197 Poster Presentations
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